[Optimization of hepatoprotective therapy of viral hepatitis with consideration of neuromediatory link of pathogenesis].
OBJECTIVE
To study therapeutic efficacy of hepatoprotective modalities on the experimental hepatitis model and in patients with parenteral hepatitis B and C regarding neurogenic amines and their coefficients.


METHODS
38 hepatoprotectors were screened for the highest activity in 1000 white rats with toxic hepatitis. Blood catecholamines (CA), histamine (H), serotonin (S), 11-oxycorticosteroids (11-OCS) were studied in 100 patients with acute hepatitis B and C.


RESULTS
The recommended hepatoprotectors optimized treatment of hepatitis, led to rapid correction of abdominal and dyspeptic syndromes, normalization of bilirubin, alkaline phosphatase, cytolysis enzymes levels, improvement of neuromediatory balance. Six-month follow-up demonstrated improvement of biochemical indices in patients given hepatoprotectors with a confirmed action.


CONCLUSIONS
Hepatoprotectors are necessary in pathogenetic treatment of acute hepatitis B and C.
Sitnikov
I G
IG
Maleev
V V
VV
Shoshin
A A
AA
D015062:11-Hydroxycorticosteroids / Q000097:blood; D000208:Acute Disease; D000328:Adult; D000818:Animals; D002395:Catecholamines / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000503:physiopathology; D006526:Hepatitis C / Q000188:drug therapy* / Q000503:physiopathology; D006632:Histamine / Q000097:blood; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008103:Liver Cirrhosis / Q000517:prevention & control*; D008297:Male; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000097:blood
D015062:11-Hydroxycorticosteroids; D002395:Catecholamines; D020011:Protective Agents; D012701:Serotonin; D006632:Histamine